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1  Introduction
Personalised medicine (PM) is new approach to
health care. It focuses on the study of the diffe-
rences in drug response among group of indivi-
duals who share common genetic or phenotypic
characteristics (Lindpaintner, 2003). 
PM has improved the understanding of disea-
se and drug response and is enabling better
approaches to target discovery and drug develop-
ment (Shah, 2004). Response to drugs has a gene-
tic and/or phenotypic component and genetic
and/or phenotypic variations among groups of indi-
viduals determine how they respond to drugs (Evans
and Johnson, 2001). These differences are identi-
fied through biomarkers that (when transformed
into companion diagnostics) have the potential of
improving the safety and efficacy of both licensed
drugs (blockbuster drugs) and drugs under deve-
lopment (minibuster drugs) (Lewis, 2003, Webster
et al., 2004). For this, PM has been defined by two
technological trajectories illustrated in figure 1).
The first one focuses on safety, the second on effi-
cacy (Hedgecoe and Martin, 2003). 
However, despite the promises around PM, few
companion diagnostics have been launched to the
market, most of these directed to drugs under deve-
lopment (i.e. Gleevec® in Philadelphia chromoso-
me-positive chronic myelogenous leukemia, Her-
ceptin® in HER2-positive breast cancer or Iressa™
and Tarceva™ in EGFR-positive lung cancer). Until
now, the pharmaceutical industry has been more
focused in the use of  PM to drugs that are being
developed rather than to drugs which are 10-50
years old (Human Genetics Commission, 2002). 
Pharmaceutical companies urge to find strate-
gies to face the decrease in the number of chemi-
cal entities to market. Despite the increase in
research and development budgets over the last
decade, the drug industry has been suffering a
decrease in the number of marketing applications
and approvals (Arnold and Hall, 2005). An increa-
sing number of failures during regulatory appro-
val, problems in the characterizing drug-dose effects
and difficulties in measuring the risk-benefit ratio
of new drugs have been at the origin of the pro-
blem (Di Masi et al., 2003). The increasing number
of failures during  regulatory approval, problems
characterising drug-dose effects and difficulties
measuring the risks benefit ratio of new drugs have
accelerated the decrease of chemical entities to
market (Di Masi et al., 2003). In addition, the con-
straints on clinical development due to a higher
burden from regulators, the need to develop com-
plex products with longer clinical development pro-
cesses to ensure effectiveness in chronic patients
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and special sub-populations, and the need to carry
these trials globally were some of the additional
barriers in drug development (Milne, 2002). 
Any new medicinal compound entering Phase
I clinical trials have only an estimated 8% chance
of reaching the market (FDA, 2004) and, even after
approval, drugs may be withdrawn because of safety
concerns. From 1990 to 2006, 38 drugs were with-
drawn from major markets due to safety problems
(Shah, 2006). Between 1998 and 2002 the avera-
ge annual number of new drugs approved by the
FDA was 68, by 2003, this number had dropped by
two-thirds. In 2004 the number of approved drugs
was 21 (Need et al., 2005). 
2 Scope,  research questions and hypo-
thesis
This paper analyses, retrospectively, the tech-
nological trajectory of TPMT testing and the pro-
cess of clinical uptake by the UK National Health
Service (NHS) until 2009. The purpose of the TPMT
case study is analysing the main enablers and bar-
riers during the introduction of TPMT testing in the
NHS as well as the major hurdles associated to the
process of reimbursement. In particular, the paper
addresses the following questions:
What were the main drivers and barriers that
facilitated and/or hindered the use of TPMT tes-
ting in the NHS?
How have these drivers and barriers shaped the
process of technology diffusion?
These questions are answered assuming the
following hypothesis:
The use of companion diagnostics or pharma-
codiagnostics for improving the safety of off-
patent drugs in the UK is less formalised than
the use of companion diagnostics to improve
the efficacy of drugs under development, becau-
se the reimbursement system for pharmacodi-
agnostics in the UK, is not designed to evalua-
te the unmet need of diagnostic or pharmaco-
diagnostics tests but their business potential.
3  Conceptual Framework
The conceptual framework used in this case
study lies in three bodies of literature: diffusion of
innovations theory and user-producer interactions
to explain the process of technological diffusion
and, socio-technical systems to explain the con-
text of the diffusion.
3 . 1  Diffusion of innovations theory
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Figure 1  Shift from a trial and error model of drug prescription to a personalised form of drug use to improve either 
safety or efficacy. 
Personalised medicine model
Trial and error model
IMPROVE-
MENT IN
EFFICACY
IMPRO-
VEMENT
IN SAFETY
Diagnostic
testing
DISEASE
GOOD RESPONSE
BLOCKBUSTER DRUG ADVERSEEVENT ALTERNATIVE DRUG
MINIBUSTER DRUG
50
The adoption and implementation of innovati-
on has been traditionally explained through con-
cepts addressed in the diffusion of innovation lite-
rature, which classical approach was developed by
Rogers (Rogers, 1962). This model understands dif-
fusion as the spread of ideas, mainly by imitation,
with a special emphasis on the influence of social
networks and how opinion leaders and individuals
take adoption decisions. This concept stands on
five principles: (1) the degree to which the innova-
tion is perceived as being better than the previous
one (relative advantage); for instance whether it
represents an advantage in effectiveness and cost-
effectiveness; (2) the extent to which it is percei-
ved as being consistent with the existing values,
professional norms and ways of working (compa-
tibility); (3) the complexity of the innovation, the
barriers that need to be overcome and its difficul-
ty of being used; (4) the possibility of experimen-
ting with the innovation (trialability) and (5) the
degree to which its results are visible to the inten-
ded adopters (observability). Innovation would be
more easily adopted if the potential adopters could
adapt and modify (or “reinvent”) the innovation to
suit their own needs and innovations would be
more rapidly “diffused” the more they complied
with these principles. 
This model was adapted by medical sociologists
to explain the introduction of tetracycline in clini-
cal practice (Coleman et al., 1966).  However, Rogers’
five step unidirectional rule is not applicable to
medical innovation for various reasons. 
The diffusion of medical technologies involves
a variety of actors and institutions, who need
to align their differing interests through a pro-
cess of collective social learning that will lead
to the acceptance of certain technological tra-
jectories and the rejections of others (Dosi, 1982).
Technological change in medicine relies on a
series of feedback mechanisms among users
and producers, who engage in a series of inter-
actions that contribute to the re-shaping of the
innovation (Gelijns and Rosenberg, 1994). In
addition, medical innovation is highly regula-
ted, both at the point of development and deli-
very and these regulations are also involved in
these feedback mechanisms.
According to Rogers, consumers are the final
users of the innovation. However, in the case
of medical innovation, clinicians are often the
gatekeepers of treatments and, in effect, the
final users. 
3 . 2  User- Producer Interactions
While evolutionary economics and business stu-
dies focus on the production-side and the creati-
on of knowledge and innovation, with less atten-
tion to the user side, innovation studies focus their
attention on the co-evolution of technologies and
markets (Coombs et al., 2001). The adoption of
medical technology is neither a passive nor a uni-
directional. The diffusion of technological innova-
tion responds to a series of interactions and feed-
back mechanisms between the users and the devel-
opers of a technology, with the demand and sup-
ply forces determining these feedback processes
(Gelijns and Rosenberg, 1994). 
Von Hippel proposed that innovation proces-
ses are distributed across users, manufacturers,
suppliers and others, highlighting the importance
of shifting from manufacturers-as-innovators into
user-producer interactions as a source of innova-
tion (Von Hippel, 1988). According to Von Hippel,
these user-producer interactions control the sur-
vival of new technological artefacts in the market
and ensure a demand for them (Von Hippel, 2005).
In medicine, these user-producer interactions
often take place among clinicians who prescribe
drugs to patients, patients who may report adver-
se events to clinicians, clinicians feeding this infor-
mation to regulatory agencies and regulatory agen-
cies or pharmacodiagnostics  informing the manu-
facturers about safety and suspected adverse events.
3 . 3  Socio- technical systems
The diffusion of medical innovations is social-
ly constructed and continuously negotiated bet-
ween the members of the organisation (Green-
halgh, 2005). Medical innovations are embedded
in a complex socio-economic environment formed
by health organisations, institutions, regulations,
communities of practitioners or patient organisa-
tions. This network explains how technology emer-
ges, develops and translates into the clinic. This
implies a co-evolution and a co-shaping of the tech-
nical as well as the socio-economic (Bijker and Law,
1992), therefore, any new medical technology will
only reach the clinic when the complex elements
that form its socio-technical network are such that
enables the translation.  
For the purpose of this study we considered that
TPMT testing formed a socio-technical system com-
posed of actors with different technological views
and positions about the technology. These actors
include researchers, clinicians, regulators, private
companies, patient groups and policy-makers.
The core of this case study lies in understan-
ding the evolution of the socio-technical network
defined by TPMT testing.
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4 Methods
The methods used in this case study were aimed
at gathering arguments and opinions for and
against the use of TPMT testing in order to inform
its technological trajectory. The research methods
were qualitative and were divided in two phases,
first secondary research (document analysis) fol-
lowed by observational research and interviews
(primary research). 
4. 1  Document Analysis
A first exploratory document search gathered
technical information on TPMT testing. The sour-
ces of evidence consulted were biological and medi-
cal journals, published socio-economic studies,
reports, product brochures, newspaper articles and
unpublished work. The desk research was also inten-
ded to look for secondary data that could support
the information obtained, at a later stage during
the interview process. Secondary data was obtai-
ned from government publications, regulations,
clinical trial protocols and patents. All these docu-
ments provided empirical information about TPMT
testing and illustrated ongoing debates around the
use of the test.
4. 2  Semi- Structured Interviews
The aim of the interview process was (1) valida-
ting the desk research and (2) obtaining views from
key informants that provided reliable opinion about
the benefits and hurdles of introducing TPMT tes-
ting in clinical practice. Interviewees were first
selected from the literature and then followed a
snowball sampling process where each intervie-
wee appointed other experts.
Interviewees were clustered into groups of
experts: researchers (formed by geneticists, bio-
chemists, pharmacologists, medical researchers,
health economists and sociologists), clinicians (hae-
matologists, oncologists, gastroenterologists and
rheumatologists) and regulators. Interviews were
tailored to each of these groups of experts. A total
of sixteen interviews was undertaken. Seven inter-
viewees were life science researchers, all of them
involved in TPMT testing, in either research only or
research and service provision (in the case of NHS
laboratories). Three were social science researchers
with expertise in TPMT testing, four were clinici-
nas (one rheumatologist, two haematologists and
a gastroenterologist) and another four were experts
in personalised medicine not specific to TPMT tes-
ting. One commercial company involved in a test
(not related to TPMT testing) was also interviewed
as well as two respondents with a regulatory affi-
liation. These were involved in regulating pharma-
ceuticals and, although they had extensive knowled-
ge about PM, they were not directly involved in the
TPMT testing case.
A patient organisation did not agree for an inter-
view as it considered PM was not relevant for them.
Three other patient organisations did not respond.
5  TPMT Testing in the UK
TPMT testing is a pharmacodiagnostic tool that
determines the levels of the enzyme Thiopurine
Methyltransferase (TPMT) in the blood. This test
predicts the likelihood of experiencing a serious or
very serious adverse event to the thiopurine drugs
azathioprine and 6-mercaptopurine, both off patent.
Thiopurines (Azathioprine-Imuran® and 6-Mer-
captopurine-Purinethol®) are immunosuppressants
used, since they were first marketed in the late
1950s by Wellcome (later on Glaxo and now GSK),
for treating patients undergoing organ transplant
surgery. Although these drugs were firstly aimed
at avoiding transplant rejection, they were later on
used to treat autoimmune conditions, mainly in
dermatology (dermatomyositis, pemphigus vulga-
ris), rheumatology (systemic lupus erythematosus)
and gastroenterology (Chron’s Disease, Ulcerative
Cholitis), as well as in haematology to treat acute
lymphoblastic leukaemia. Thiopurines, as well as
any other drugs, have associated side-effects, prin-
cipally a reduction in the production of blood cells
that can seriously compromise the patient’s health.
As a consequence, patients treated with these drugs
need to be closely monitored (full blood count, liver
function tests and electrolyte analysis) on a wee-
kly basis, until the treatment is stabilised. 
Some of the adverse events caused by thiopu-
rines have been associated with low levels of or the
lack of the enzyme Thiopurine Methyltransferase
(TPMT) (Black et al., 1998, Arenas et al., 2006). Accor-
ding to the levels of the enzyme in the blood,
patients can be advised not to take the drug or be
prescribed a lower dose; however, the response to
azathioprine has also a genetic component and,
mutations in the gene that codes for the TPMT
gene can also be associated with adverse events
(Coulthard et al., 2004, Coulthard and Hogarth,
2005, Arenas et al., 2006). However, the correlati-
on between enzyme levels (phenotype) and muta-
tions (genotype) is not fully understood and tes-
ting for the enzyme levels is more effective in most
cases than looking for genetic mutations. Only
some of the mutations implicated in drug respon-
se are known. 
For ALL the situation was different. TPMT tes-
ting was part of a clinical  trial ALL, where every
child diagnosed with ALL underwent TPMT testing.  
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The major benefit of TPMT testing (phenotyp-
ic test) is diagnosing who is at risk of a severe ADR,
which may be fatal. It is estimated that only 0.3%
of the population might be exposed to that level
of risk, 10% of the population might be at a mode-
rate risk (not as severe) and the remaining 90%
may develop a normal drug response. In the UK
there are two NHS reference laboratories that offer
TPMT testing although the test is not extended
across the clinical community (Farguer et al., 2006).
There are various reasons for this:
TPMT testing in the UK is a laboratory develo-
ped or home-brew test. It is not a commercial
kit as it does not comply with the In Vitro Diag-
nostics (IVD) Directive that rules the marketing
of commercial diagnostic tests. On the contra-
ry, it is a non-commercial test developed by NHS
laboratories. 
The National Institute of Clinical Excellence
(NICE), who is the main reimbursement body
in the UK and decides which drugs and techno-
logies should be adopted by the NHS, has not
appraised the test. As a consequence, TPMT tes-
ting is not reimbursed at a central level. Indivi-
dual primary care consortia (former Primary
Care Trusts) may reimburse TPMT testing at a
local level if they consider testing useful and
necessary. 
In the lack of a formal evaluation of the test,
there are different patterns of uptake between
dermatologists, rheumatologists, gastroente-
rologists and haematologists (Payne et al., 2007).
The British Society of Dermatologists considers
that TPMT testing should be considered befo-
re prescribing azathioprine (Anstey et al., 2004),
the British Society of Rheumatology has also
adhered to this recommendation (Payne et al.,
2007); however, the British Society of Gastro-
enterologists does not recommend TPMT tes-
ting as it considers that azathioprine has been
widely used in Ulcerative Colitis and Crohn’s
Disease and has proved to be safe (Teml et al.,
2007).
6 TPMT testing in the UK Reimbursement
System
The translation of any drug or medical techno-
logy into clinical practice requires a demonstrati-
on of comparative safety, efficacy and cost-effecti-
veness, together with other factors like disease
severity as well as other ethical, social and legal
implications (Shah, 2004). 
In the UK, NICE is the official body that decides
on reimbursement at a national level. NICE evalua-
tes primarily drugs but, since 2009 it also started
evaluating diagnostics. NICE has a pragmatic view
on how its decisions should be made and only
recommends treatments below the threshold of
£30,000 per Quality-Adjusted-Life Years (QALY).
TPMT testing emerged as a tool to predict adver-
se events originated by two off-patent drugs: AZA
and 6-MP. Both AZA and 6-MP are reimbursed by
the NHS because both drugs had been used befo-
re NICE started appraising technologies and becau-
se both are off-patent and therefore cheap drugs.
The drugs cost approximately £20 a month (data
provided by clinicians in 2007. The 2013 BNF cost
of a pack of 28 pills of 25 mg is £6.02 .), while the
test, £27 per patient (costs for 2007). But despite
AZA is reimbursed by the NHS, TPMT testing is not,
because NICE has not appraised the test and, wit-
hout a “stamp” of approval that assures clinical
utility, it is difficult for the NHS to justify reimbur-
sement. Nevertheless and, despite  TPMT was not
appraised by NICE, the two National Reference
Laboratories (at Birmingham City Hospital and
Guy´s Hospital in London) offer TPMT testing to
the NHS since 2003. As a result, some hospitals
reimburse the test locally, depending on  the cash
balance of the NHE Trust or hospital as well as on
other factors such as the clinician’s willingness to
prescribe the test or their proximity or connecti-
ons with the testing laboratory.
6. 1  Service Delivery
Once a TPMT test is requested by a clinician, the
patient signs a consent form and a sample is sent
to one of the reference laboratories. The laborato-
ry sends a report back within 6 working days, with
a narrative interpretation, in which they assign a
high or low risk of myelotoxicity and warn of the
need for cautious use of AZA or 6-MP, although the
report is only a recommendation.  Depending of
the levels of TPMT in blood, patients can be classi-
fied as:
Low risk: the patient is normal (his/her TPMT
levels are normal or even higher than normal)
Higher risk than normal (TPMT levels are low)
and azathioprine should be taken with caution
(clinicians often reduce the dose by half).
High risk (levels of TPMT are very low or non-
existent) and should not be given azathiopri-
ne.
Clinical demand varies across specialties. During
the first year of service, referrals to Birmigham City
Hospital came from the following clinical special-
ties: gastroenterology (66.7%), dermatology (13.6%),
rheumatology (12%) and other specialties (7.7%)
(Graham et al., 2004), with demand increasing in
the following years. By diseases treated, TPMT tes-
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ting was requested in patients with Crohn’s Disea-
se (27.5%), Ulcerative Colitis (31.9%), Inflammato-
ry Bowel Disease (4.8%), Systemic Lupus Erythema-
tosus (4.4%), Dermatitis/Eczema (7.2%), Bullous
Pemphigoid (6.3%) and others (7.6%) (Graham et
al., 2004). It should be noted here that the high
demand in gastroenterology is due to the high volu-
me of patients in this specialty taking azathiopri-
ne, which outweighs the lack of recommendation
for testing in gastroenterology.
7  Drivers for TPMT testing uptake
The main factors influencing testing uptake are
the following:
Promoters of TPMT testing argue that, the bene-
fits of testing are substantial, not only for
patients who have low or no TPMT levels and
should not be taking the drug, but also for people
with intermediate levels, who could benefit
from a reduction in the AZA dose. 
The reference laboratories suggest that TPMT
testing is cost-effective on the basis that it pre-
vents serious AEs, which treatment costs are
very high. Some studies have shown that TPMT
enzyme test is also cost-effective in certain situa-
tions (Payne et al., 2009, Graham et al., 2004,
Gurwitz et al., 2009).
Some clinical groups have recommended TPMT
testing. The British Association of Dermatolo-
gy  was the first group to recommended tes-
ting, as a result, all dermatologists across the
UK now refer their patients for a test before
prescribing AZA (Anstey et al., 2004). Subse-
quently, the British Society of Rheumatologists
also included TPMT testing as an option to
patients on AZA. As a result, the demand for
test increased among rheumatologists (Payne
et al., 2007).
In 2007, some hospitals in the UK (approxima-
tely 20 NHS Trusts) have established TPMT pre-
screening policies, meaning that they have
implemented TPMT testing and cover the cost
of testing.
Some respondents believe TPMT testing may
prevent bone marrow failure in ALL patients,
particularly when routine blood tests could not
detect it. 
Phenotyping or measuring TPMT enzyme levels
in blood appears to be the best form of testing.
The enzyme assay gives more information than
the genetic assay, which only looks at the most
common polymorphisms that affect drug
response.  But not all polymorphisms that influ-
ence drug response are known and even if they
were, doing a genetic analysis of all of them
would be too costly and too lengthy. For this
reason, genotyping is an option, only when phe-
notyping does not give a conclusive indication.
8 Barriers for TPMT testing uptake
Even though TPMT testing is already available
at the NHS, there are a number of reasons why the
diffusion of the test is slow and remains, in some
instances controversial:
The clinical opinions about testing are contra-
dictory. While some haematologists consider
the test effective and necessary, others believe
that TPMT testing would not replace routine
blood monitoring and electrolyte analysis. 
Not all clinical associations believe the test has
an additional benefit. The British Society of Gas-
troenterology has never included TPMT testing
in its recommendations (Carter et al., 2004).
There is not a formal evaluation of TPMT test
and, the lack of consensus on TPMT testing
across specialties makes the situation compli-
cated. It is not clear whether not doing a TPMT
test could incur in malpractice. 
Neither of the TPMT cost and economic studies
studies have been considered in any of the deci-
sions on TPMT testing.
9 Discussion
TPMT testing exemplifies a case where PM can
improve the efficacy of licensed drugs. Even
thoughTPMT was one of the first biomarkers of
drug response discovered and the indications that
testing could predict serious AEs, the test has not
been added to the product license of AZA or 6-MP.
In 2003, the Department of Health (DoH) publis-
hed a white paper announcing funding for research
in PM and genetics and encouraging researchers
to look for specialised service delivery mechanisms.
According to this white paper, “...patients could
undergo a test to predict their response or ensure
medicine and doses are right at the first time”. This
was particularly relevant to patients at risk of AEs
as, only in the UK, AEs were estimated to affect 7%
of hospital admissions at an annual cost of £380
million to the NHS in England alone (DoH 2003).
In addition, the DoH added that “...the logistics
and clinical utility of including a test in prescribing
decisions will need careful evaluation, but apply-
ing this knowledge within primary care should sig-
nificantly improve patient outcomes in medicines
use” (DoH 2003). However, to date, TPMT testing
has not received a careful evaluation by NICE or
any other UK reimbursement body, even if TPMT
is a well known biomarker and testing facilities are
available at the NHS.
Since NICE launched its diagnostics assessment
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programme in 2009, evaluations have focused on
commercial diagnostics rather than home-brew
tests (such as TPMT testing), even if these addres-
sed an unmet need. This verifies the hypothesis
that, the UK evaluation system for medical devi-
ces is not designed to address products for an unmet
need, if these do not have business potential. But,
despite the lack of institutional support, TPMT tes-
ting has been introduced in clinical practice through
alternative routes. As we have seen in the drivers
and barriers sections, the demand for testing increa-
sed considerably after two reference laboratories
started offering testing (Ford et al., 2004a, Ford et
al., 2004b, Birmingham City Hospital, 2009), follo-
wed by clinical associations including TPMT tes-
ting in their guidelines. 
TPMT testing reference laboratories acted as
lead users of the test, setting a national service
across the whole NHS. These laboratories were also
successful at optimising the technology for mea-
suring the levels of enzyme in the blood and dis-
seminating information about the benefits of tes-
ting.
The fact that two public laboratories have taken
the lead in the UK and are offering TPMT testing
services, indicates that: 
Expertise in product and service innovation in
PM and diagnostic testing is not exclusive to
the diagnostic or pharmaceutical industry. Other
actors like public laboratories are important
innovators, particularly in non-commercial diag-
nostics. 
The case of TPMT testing shows that, the imple-
mentation of PM for preventing AEs is strongly
driven by lead users who reside in public hos-
pitals. Clinicians and public laboratories are key
actors designing the technological trajectories
of PM for improving drug safety. 
PM for off-patent drugs is strongly associated
to home-brew tests developed in NHS labora-
tories. However, private companies could threa-
ten public service provision, if other commerci-
al alternatives emerged and/or if alternative
commercial tests were reimbursed.
Peer opinion exerts a strong influence on clini-
cal acceptance and demand for testing. Profes-
sional guidelines are strong drivers for techno-
logy adoption, for this reason, even though TPMT
testing had not been appraised by NICE, it has
been recommended by some clinical associati-
ons and requested by certain clinics and hospi-
tals.
1 0 Conclusion
Market access for drugs and commercial diag-
nostics lies on the demonstration of safety, effica-
cy and cost-effectiveness, assessed by regulatory
and reimbursement agencies. The case of TPMT
testing, however, shows that PM for off-patent
drugs is associated to non-commercial diagnos-
tics. These do not follow the same evaluation pro-
cedures than commercial tests. The case of TPMT
testing shows that, process of diffusion of these
home-brew tests lies in public laboratories that
generate testing capabilities and disseminate
knowledge across the clinical community.
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